Upstream Bio Statistics
Total Valuation
Upstream Bio has a market cap or net worth of $446.79 million. The enterprise value is $153.32 million.
Important Dates
The last earnings date was Wednesday, May 13, 2026, before market open.
| Earnings Date | May 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Upstream Bio has 54.42 million shares outstanding. The number of shares has increased by 105.15% in one year.
| Current Share Class | 54.42M |
| Shares Outstanding | 54.42M |
| Shares Change (YoY) | +105.15% |
| Shares Change (QoQ) | +0.45% |
| Owned by Insiders (%) | 0.29% |
| Owned by Institutions (%) | 66.75% |
| Float | 35.01M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 134.49 |
| Forward PS | 226.16 |
| PB Ratio | 1.47 |
| P/TBV Ratio | 1.47 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 46.15 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 23.14, with a Debt / Equity ratio of 0.00.
| Current Ratio | 23.14 |
| Quick Ratio | 21.74 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -41.83% and return on invested capital (ROIC) is -28.57%.
| Return on Equity (ROE) | -41.83% |
| Return on Assets (ROA) | -27.76% |
| Return on Invested Capital (ROIC) | -28.57% |
| Return on Capital Employed (ROCE) | -56.50% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | $44,293 |
| Profits Per Employee | -$2.09M |
| Employee Count | 75 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -10.37% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -10.37% |
| 50-Day Moving Average | 9.25 |
| 200-Day Moving Average | 18.48 |
| Relative Strength Index (RSI) | 37.98 |
| Average Volume (20 Days) | 521,475 |
Short Selling Information
The latest short interest is 3.22 million, so 5.92% of the outstanding shares have been sold short.
| Short Interest | 3.22M |
| Short Previous Month | 3.02M |
| Short % of Shares Out | 5.92% |
| Short % of Float | 9.21% |
| Short Ratio (days to cover) | 5.29 |
Income Statement
In the last 12 months, Upstream Bio had revenue of $3.32 million and -$156.76 million in losses. Loss per share was -$2.90.
| Revenue | 3.32M |
| Gross Profit | 3.32M |
| Operating Income | -171.96M |
| Pretax Income | -156.76M |
| Net Income | -156.76M |
| EBITDA | -171.77M |
| EBIT | -171.96M |
| Loss Per Share | -$2.90 |
Full Income StatementBalance Sheet
The company has $294.58 million in cash and $1.11 million in debt, with a net cash position of $293.47 million or $5.39 per share.
| Cash & Cash Equivalents | 294.58M |
| Total Debt | 1.11M |
| Net Cash | 293.47M |
| Net Cash Per Share | $5.39 |
| Equity (Book Value) | 304.00M |
| Book Value Per Share | 5.59 |
| Working Capital | 302.61M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$139.96 million and capital expenditures -$165,000, giving a free cash flow of -$140.13 million.
| Operating Cash Flow | -139.96M |
| Capital Expenditures | -165,000 |
| Depreciation & Amortization | 194,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -140.13M |
| FCF Per Share | -$2.57 |
Full Cash Flow StatementMargins
| Gross Margin | 100.00% |
| Operating Margin | -5,176.49% |
| Pretax Margin | -4,718.96% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Upstream Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -105.15% |
| Shareholder Yield | -105.15% |
| Earnings Yield | -35.09% |
| FCF Yield | -31.36% |
Analyst Forecast
The average price target for Upstream Bio is $42.43, which is 416.81% higher than the current price. The consensus rating is "Buy".
| Price Target | $42.43 |
| Price Target Difference | 416.81% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | 102.06% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Upstream Bio has an Altman Z-Score of 36.77 and a Piotroski F-Score of 1.
| Altman Z-Score | 36.77 |
| Piotroski F-Score | 1 |
